Detalles de la búsqueda
1.
Heart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment landscape.
Heart Fail Rev
; 29(3): 631-662, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38411769
2.
Attitudes and beliefs of the French public about schizophrenia and major depression: results from a vignette-based population survey.
BMC Psychiatry
; 13: 313, 2013 Nov 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-24252540
3.
Value added medicines: what value repurposed medicines might bring to society?
J Mark Access Health Policy
; 5(1): 1264717, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28265347
4.
Gene therapies development: slow progress and promising prospect.
J Mark Access Health Policy
; 5(1): 1265293, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28265348
5.
Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines.
J Mark Access Health Policy
; 5(1): 1355202, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28804603
6.
Key drivers for market penetration of biosimilars in Europe.
J Mark Access Health Policy
; 5(1): 1272308, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28265349
7.
Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry.
J Mark Access Health Policy
; 5(1): 1381544, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29081924
8.
Supply-side and demand-side policies for biosimilars: an overview in 10 European member states.
J Mark Access Health Policy
; 5(1): 1307315, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28740617
9.
Analysis of health economics assessment reports for pharmaceuticals in France - understanding the underlying philosophy of CEESP assessment.
J Mark Access Health Policy
; 5(1): 1344088, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28804600
10.
Advanced therapy medicinal products: current and future perspectives.
J Mark Access Health Policy
; 42016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27123193
11.
Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials.
J Mark Access Health Policy
; 42016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27570614
12.
French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends.
Target Oncol
; 11(4): 515-34, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-26830301
13.
Conflict of interest in Health Technology Assessment decisions: case law in France and impact on reimbursement decisions.
J Mark Access Health Policy
; 3(1): 25682, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-29785249
14.
Market access pathways for cell therapies in France.
J Mark Access Health Policy
; 32015.
Artículo
en Inglés
| MEDLINE | ID: mdl-27123176
15.
Current process and future path for health economic assessment of pharmaceuticals in France.
J Mark Access Health Policy
; 32015.
Artículo
en Inglés
| MEDLINE | ID: mdl-27123173
16.
Overview of external reference pricing systems in Europe.
J Mark Access Health Policy
; 32015.
Artículo
en Inglés
| MEDLINE | ID: mdl-27123181
17.
A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments.
J Mark Access Health Policy
; 32015.
Artículo
en Inglés
| MEDLINE | ID: mdl-27123190
18.
Continuum beliefs and attitudes towards people with mental illness: Results from a national survey in France.
Int J Soc Psychiatry
; 61(3): 297-303, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25061023
19.
Routine clinical assessment of cognitive functioning in schizophrenia, major depressive disorder, and bipolar disorder.
Eur Neuropsychopharmacol
; 24(1): 133-41, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24314852
20.
Pharmaceutical expenditure forecast model to support health policy decision making.
J Mark Access Health Policy
; 22014.
Artículo
en Inglés
| MEDLINE | ID: mdl-27226830